Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 who are able to give written consent to participate
- People who have been diagnosed (confirmed by tissue testing) with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back or stopped responding to standard treatment, and who have already received at least 2 prior treatment regimens
- People whose cancer can be measured on scans (per standard research criteria) and who are generally well enough to carry out light activity or normal daily tasks
- People who have a tumour tissue sample available for testing, and whose tumour shows enough of the specific targets the trial is studying (the trial team will assess this using a laboratory test on the tissue sample)
- People with healthy enough kidney, liver, blood, and organ function as defined by the trial, and who have a negative pregnancy test and agree to use effective contraception for a period defined by the trial after receiving the treatment
Who may not be able to join:
- People with active cancer spread to the brain or the lining around the brain, unless it has been treated and has been stable for a period defined by the trial
- People who have previously received a gene-modified cell therapy targeting any of the specific proteins this trial studies (GD2, MUC1, PSMA, or mesothelin) within the last 6 months
- People with an active, uncontrolled infection, including uncontrolled HIV, hepatitis B, hepatitis C, or an active systemic fungal infection
- People with serious heart conditions, such as a recent heart attack, unstable chest pain, an uncontrolled irregular heartbeat, or a heart pumping function below 50%
- People with an active autoimmune disease that required immune-suppressing medication in the 14 days before the trial's preparatory treatment phase (routine low-dose steroid replacement may be permitted — confirm with trial site)
- People who have previously had an organ transplant or a bone marrow/stem cell transplant from another person
- People who are pregnant or breastfeeding
- People whose overall health or circumstances, in the treating doctor's judgement, could put them at risk or affect their ability to safely take part
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 13076790030
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose-limiting toxicities (DLTs) to determine maximum tolerated dose (MTD); Incidence, severity, and relatedness of adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.